Cargando…

Lingo-1: a novel target in therapy for Alzheimer's disease?

Detalles Bibliográficos
Autores principales:	Fernandez-Enright, Francesca, Andrews, Jessica L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774240/ https://www.ncbi.nlm.nih.gov/pubmed/26981092 http://dx.doi.org/10.4103/1673-5374.175048

Ejemplares similares

Novel implications of Lingo-1 and its signaling partners in schizophrenia
por: Fernandez-Enright, F, et al.
Publicado: (2014)

LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
por: Jain, Arvind, et al.
Publicado: (2017)

Perinatal administration of phencyclidine alters expression of Lingo-1 signaling pathway proteins in the prefrontal cortex of juvenile and adult rats
por: Andrews, Jessica L., et al.
Publicado: (2018)

Programación en Lingo /
por: Pescador Albiach, Darío
Publicado: (1997)

Lingo dictionary : Director, version 4.
Publicado: (1994)

Using lingo : Director, version 4.
Publicado: (1994)

Lingo : guía de Europa para el turista lingüístico /
por: Dorren, Gaston
Publicado: (2017)

Programación avanzada con Lingo /
por: Julius, Tab, 1962-
Publicado: (1997)

Director 8 and Lingo authorized
por: Gross, Phil, et al.
Publicado: (2000)

Nogo-A and LINGO-1: Two Important Targets for Remyelination and Regeneration
por: Kalafatakis, Ilias, et al.
Publicado: (2023)

Genetic and Epigenetic Regulation in Lingo-1: Effects on Cognitive Function and White Matter Microstructure in a Case-Control Study for Schizophrenia
por: Andrews, Jessica L., et al.
Publicado: (2023)

Retinoic acid keeps Lingo-1 quiet
por: Short, Ben
Publicado: (2011)

LINGO1 Variants in the French-Canadian Population
por: Bourassa, Cynthia V., et al.
Publicado: (2011)

Curso de Lingo para Windows /
por: Thompson, John, 1959-
Publicado: (1996)

Acid-sensing ion channel 1a: a novel target in Alzheimer’s disease?
por: Mango, Dalila, et al.
Publicado: (2022)

Targeting immunometabolic pathways for combination therapy in Alzheimer's disease
por: Erichsen, Jennifer, et al.
Publicado: (2023)

LINGO-1 and AMIGO3, potential therapeutic targets for neurological and dysmyelinating disorders?
por: Foale, Simon, et al.
Publicado: (2017)

LINGO-1 and Neurodegeneration: Pathophysiologic Clues for Essential Tremor
por: Zhou, Zhi-dong, et al.
Publicado: (2012)

Copy number variation of LINGO1 in familial dystonic tremor
por: Alakbarzade, Vafa, et al.
Publicado: (2019)

Director 7 y Lingo para Windows
por: Gross, Phil
Publicado: (1999)

Director 8.x / Lingo práctico : guía de aprendizaje
por: Burgos, Daniel
Publicado: (2000)

Director 7.x / Lingo práctico : guía de aprendizaje /
por: Burgos, Daniel
Publicado: (2000)

Lingo in a nutshell: a desktop quick reference
por: Epstein, Bruce A
Publicado: (1998)

New unexpected role for Wolfram Syndrome protein WFS1: a novel therapeutic target for Alzheimer’s disease?
por: Chen, Shuo, et al.
Publicado: (2022)

LINGO-1 promotes lysosomal degradation of amyloid-β protein precursor
por: de Laat, Rian, et al.
Publicado: (2015)

Advancing combination therapy for Alzheimer's disease
por: Salloway, Stephen P., et al.
Publicado: (2020)

Newfound physiological function of FAIM protein offers hope of novel disease-modifying therapy for Alzheimer’s disease
por: Balaj, Allison R., et al.
Publicado: (2023)

Heparan sulfate proteoglycans and heparanases in Alzheimer's disease: current outlook and potential therapeutic targets
por: Lorente-Gea, Laura, et al.
Publicado: (2017)

Tetrahydrohyperforin (IDN5706) targets the endoplasmic reticulum for autophagy activation: potential mechanism for Alzheimer's disease therapy
por: González, Alexis, et al.
Publicado: (2016)

Choroidal Proteins Involved in Cerebrospinal Fluid Production may be Potential Drug Targets for Alzheimer’s Disease Therapy
por: Wostyn, Peter, et al.
Publicado: (2011)

Targeting the guanine-based purinergic system in Alzheimer's disease
por: Lanznaster, Débora, et al.
Publicado: (2017)

Dual targeting nano-approaches for Alzheimer's disease etiology
por: Hettiarachchi, Sajini D., et al.
Publicado: (2020)

Targeting the transferrin receptor to develop erythropoietin for Alzheimer's disease
por: Sumbria, Rachita K.
Publicado: (2020)

TREM2 as an evolving therapeutic target in Alzheimer’s disease
por: George, Jacob
Publicado: (2023)

Blocking LINGO-1 in vivo reduces degeneration and enhances regeneration of the optic nerve
por: Gresle, Melissa M, et al.
Publicado: (2016)

Anti-LINGO-1 improved remyelination and neurobehavioral deficit in cuprizone-induced demyelination
por: Moradbeygi, Khadijeh, et al.
Publicado: (2021)

Functional activity of anti-LINGO-1 antibody opicinumab requires target engagement at a secondary binding site
por: Hanf, Karl J. M., et al.
Publicado: (2020)

Targeting abnormal metabolism in Alzheimer's disease: The Drug Repurposing for Effective Alzheimer's Medicines (DREAM) study
por: Desai, Rishi J., et al.
Publicado: (2020)

Vascular dysfunction in Alzheimer’s disease: a biomarker of disease progression and a potential therapeutic target
por: Govindpani, Karan, et al.
Publicado: (2019)

Anti-LINGO-1 has no detectable immunomodulatory effects in preclinical and phase 1 studies
por: Ranger, Ann, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qqe3dtehcf8o7prd0brpv7t7to